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We identified 19 cases carrying extremely rare SORL1 loss-of-function variants among a 1 6 collection of 6,965 cases and a single loss-of-function variant among 13,252 controls (p = 2.17 x 1 7 Introduction 1 3 4 tranche of 95%. Finally, read-backed phasing was performed to determine phased SNVs and 1 3 5 merge multinucleotide variants (MNVs) when appropriate. Variants were annotated using Clin-1 3 6
Eff with Ensembl-GRCh37.73 annotations. Quality thresholds were set based on previous work 5, 6 , such that all resulting exome variants 1 3 9 had a quality score of at least 50, quality by depth score of at least 2, genotype quality score of 1 4 0 at least 20, read position rank sum of at least -3, mapping quality score of at least 40, mapping 1 4 1 quality rank sum greater than -10, and a minimum coverage of at least 10. SNVs had a 1 4 2 maximum Fisher's strand bias of 60, while indels had a maximum of 200. For heterozygous 1 4 3 genotypes, the alternative allele ratio was required to be greater than or equal to 25% and Quality control was performed on all sequencing data. Samples with less than 90% of the 1 4 8 consensus coding sequence (CCDS) covered at 10X and samples with sex-discordance 1 4 9 between clinical and genetic data were excluded from the analysis. Cryptic relatedness testing 1 5 0 was performed using KING, and second degree or closer (relatedness threshold of 0.0884 or 1 5 1 greater) relatives were removed with preferential retention of cases over controls and 1 5 2 subsequently samples with higher average read-depth coverage. The consensus coding sequence 11 (CCDS) annotated protein-coding region for each gene 1 5 5 (n=18,834) was tabulated as either carrying or not carrying a qualifying variant for every bias due to coverage differences between cases and controls. To ensure balanced sequencing 1 7 1 coverage of evaluated sites between cases and controls, we imposed a statistical test of 1 7 2 independence between the case/control status and coverage. For a given site, consider s total 1 7 3 number of cases, t total number of controls and x number of cases covered at 10X, y number of 1 7 4 controls covered at 10x. We model the number of covered cases X as a Binomial random 1 7 5 variable: 1 7 6 X ∼ bin(n = number covered samples, p = P(case|covered)) 1 7 7
If case/control status and coverage status are independent, then: We can test for this independence by performing a two-sided Binomial test on the number of 1 8 0 covered samples at given site, x.
In the collapsing analyses, a binomial test for coverage balance as described above was We analyzed the exomes of 6,965 individuals meeting with the diagnosis of AD and 13,232 1 9 7 controls (Table 1) . Prior to analysis, 570 individuals (91 cases and 479 controls) were removed 1 9 8 due to known or cryptic relatedness. For ultra-rare variant analysis (MAF of 0.01% or lower), 1 9 9 conventional population stratification has not been a strong confounder as it can be in common 2 0 0 variant analyses; and these results did not significantly differ from meta-analyses in population 2 0 1 stratified data. All variants reported here were found in five or less individuals from the study, 2 0 2 and most variants were found in only one person, increasing the confidence that population 2 0 3 stratification was not an issue. An important distinction exists between the cases and controls in 2 0 4 the ADSP and WHICAP datasets. In the ADSP dataset, the younger cases were preferentially 2 0 5 chosen as part of the study design 7 . The WHICAP individuals are part of a population-based 2 0 6 cohort followed longitudinally, and thus cases were older than controls. inflation for the analysis was very modest, λ = 1.04 (Figure 1) . Gene-based, collapsing analyses 2 1 0 for loss-of-function variants, with allele frequency less than 0.01% (within the study cohort, and 2 1 1 separately within ExAC 12 ) identified SORL1 to be enriched in cases compared to controls at an 2 1 2 exome-wide significance level of p = 2.17 x 10 -8 ( Table 2) . We confirmed the results for SORL1 Whites, Caribbean Hispanics, and African Americans as described above, separately and other gene attained the study-wide level of statistical significance, GRID2IP (p = 2.98 x 10 -4 ), 2 1 7 WDR76 (p = 7.39 x 10 -4 ) and GRN (p = 9.56 x 10 -4 ) were highly-ranked candidate genes that 2 1 8 were case-enriched for loss-of-function variants ( Table 2) . Extended results are found in 2 1 9 Supplemental Table 2 . There were no significant differences in synonymous variation in these 2 2 0 four genes (1.5% cases, 1.7% of controls; FET p = 0.25). There were 19 cases with a loss-of-function qualifying variant in SORL1 (Table 3) cases (frequency = 0.27%) and one variant among 13,232 controls (frequency = 0.0076%).
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Given the rate of SORL1 loss-of-function qualifying variants found in our control sample (1 / 2 2 5 13,232; frequency = 0.0076%), we expected to identify only 0.5 loss-of-function variants by 2 2 6 chance among our 6,965 cases; however, we identified 19. The accompanying odds ratio for 2 2 7 AD risk upon identifying a SORL1 loss-of-function qualifying variants as defined in this study Of relevance to loss-of-function variant case-enrichment, SORL1 is known to be among the 2 3 4 protein-coding genes most significantly depleted of loss-of-function variants in the general 2 3 5 population (LOF depletion FDR = 2x10 -7 ) ( Table 2) . Of the 17 distinct SORL1 loss-of-function 2 3 6
qualifying variants, only one (11:121440980, rs200504189) was found in the ExAC database 12 . SORL1 was also significantly enriched for functional variants (nonsynonymous and predicted as 2 3 8 possibly or probably damaging by PolyPhen-2 HumVar 17 ) (p = 9.79x10 -7 ), 1.8% of cases had a 2 3 9 qualifying functional variant compared to 1% controls. There was no difference in the frequency 2 4 0 of APOE-ε4 carriers among cases with qualifying variants in SORL1 compared to those without 2 4 1 these variants (40.0% vs. 39.6%). Age-at-onset analyses revealed a 6.81 year difference 2 4 2 between cases with a SORL1 qualifying variant versus non-carrying cases (AD carriers: 69.86 2 4 3 +/-9.37; AD non-carriers: 76.67 +/-8.53; t(6963), p = 4x10 -4 ). Coverage for the 12 qualifying GRID2IP variants was lower in the sequencing performed in this 2 4 6 project and in ExAC 12 , reducing our confidence of the rare variant calling for this gene because coverage of the GRID2IP variants was 21-fold and at these exact same sites in ExAC 12 , 4-fold. However, read-depth coverage was higher in the genome aggregation database (gnomAD), 2 5 0 with a median of mean read-depth coverage of 21-fold, and only two loss-of-function variants 2 5 1 less than the 0.0001 allele frequency threshold. Two of the 11 cases were deceased with 2 5 2 autopsy confirming the pathological diagnosis of AD 16 . Coverage for WDR76 and GRN were excellent in this study and in ExAC 12 . Three of the 10 2 5 5 individuals clinically diagnosed as AD with loss-of-function qualifying variants in WDR76 had 2 5 6 undergone autopsy. One met postmortem criteria defined as high likelihood of Alzheimer's 2 5 7 disease, a second met intermediate likelihood 16 , however, the third had no distinctive pathology 2 5 8 and no definitive diagnosis was derived. Two of the 11 individuals with GRN loss-of-function an important genetic risk factor for AD. This is the first investigation to establish a genome-wide 2 7 1 statistically significant association between ultra-rare variants in SORL1 and AD in a large, Common variants in SORL1 were first genetically associated with AD in a candidate gene 2 7 6 analysis using 29 common variants 24 . Shortly thereafter, nine rare loss-of-function variants 2 7 7 including nonsense, frameshift and splice site mutations were described in familial and sporadic 2 7 8 early onset AD 19, 20 . The SORL1 findings in early onset AD were replicated in larger European 2 7 9 cohorts of patients 21 . Using a targeted, candidate gene approach, SORL1 variants were found European ancestry with sporadic late-onset AD 26 . Our findings here indicated that cases who for expression of SORL1 protein is in the brain especially within neurons and astrocytes. Aβ trans-Golgi network to decrease Aβ production. We found that in the absence of the SORL1 to neurodegeration in Alzheimer's disease relates to the disruption of its ability to bind APP. Qualifying variants in other genes were also more prevalent among patients with AD compared 3 0 8 with healthy, non-demented controls. Variants in GRID2IP, WDR76 and GRN were four to five 3 0 9 times more frequent in cases than in controls, though these genes have not yet achieved 3 1 0 genome-wide significance and thus further studies including larger patient samples will help 3 1 1 determine which contribute to AD risk. Glutamate receptor delta-2 interacting protein (GRID2IP) is selectively expressed in the 3 1 3 cerebellar Purkinje cell-fiber synapses. The exact role for this gene is not fully understood, but it 3 1 4 appears to be a postsynaptic scaffold protein that links to GRID2 with signaling molecules and 3 1 5 the actin cytoskeleton 27 . There is no known role for GRID2IP in AD despite the fact that variants driving the signal in our analyses are all well covered in our entire cohort, with more 3 2 0 than 96% of samples achieving at least 10X coverage. nodes. Only one of the three individuals with postmortem data met "high likelihood criteria" for GRN mutations in patients with clinically diagnosed AD have been previously reported in large families in the National Institute on Aging family-based study (NIA-AD) 28 and among large, The results here indicate that extremely rare, loss-of-function variants in SORL1 have an recycling of the amyloid precursor protein and the amyloid β protein make this pathway an 3 5 0 attractive target for the development of therapies. Beyond implicating SORL1 and highly 3 5 1 suggestive candidate genes for AD, this study shows for the first time that the collapsing 3 5 2 analysis methodology of ultra-rare variants described here that has proven successful for a 3 5 3 number of rare diseases also can securely implicate genes in a condition as common as AD. The Discovery Phase analysis of sequence data is supported through UF1AG047133 (to Drs. Goate and the Discovery Extension Phase analysis is supported through U01AG052411 to Dr. Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 
